Ready for take-off: Molecular markers for clinical management of urological malignancies

Joint meeting of the EAU Section of Urological Imaging (ESUI), the EAU Section of Uropathology (ESUP) and the EAU Section of Urological Research (ESUR)

Monday 12 July
16:00 - 17:30

Location Virtual Room 3

Chairs
K. Junker, Homburg (DE)
R. Montironi, Ancona (IT)
G. Salomon, Hamburg (DE)

Learning objectives
The first part of the session is focused on DNA damage repair (DDR) defects that are playing an important role in tumour development and progression as well as for therapy response. Somatic and germline mutations in DDR genes such as BRCA1 and BRCA2 have been found in prostate cancer. Their value for cancer risk prediction, prognosis and therapy response will be discussed. In this regard, the rationale of germline testing has to be defined considering the experience in breast cancer patients. PARP inhibitors represent new targeted therapeutic options not only in prostate but also in bladder cancer, especially in patients with DDR defects. In the second part, we will discuss progress in the field of molecular markers and their clinical relevance focusing on liquid biopsy and molecular imaging for precision medicine in urological cancers.

16:00 - 16:01
Welcome and introduction
K. Junker, Homburg (DE)

16:01 - 16:40
BRCA1, BRCA2 and beyond: Important for clinical management in urological tumours?

Moderators
I. Heidegger, Innsbruck (AT)
H.Y. Leung, Glasgow (GB)
R. Montironi, Ancona (IT)

16:01 - 16:11
DNA damage repair defects: An overview
R.G. Bristow, Manchester (GB)

16:11 - 16:21
DNA repair gene mutations in prostate cancer: Effects on outcome after primary and systemic therapy
E. Castro, Madrid (ES)

16:21 - 16:40
Panel discussion: To test BRCA: Who should be tested: when, what, by whom?

Panel
R.G. Bristow, Manchester (GB)
E. Castro, Madrid (ES)
M. Eckstein, Erlangen (DE)
M. Wunderle, Erlangen (DE)

16:40 - 17:29
Liquid biopsy and molecular imaging for precision medicine in urological cancers

Moderators
M. Colecchia, Milan (IT)
K. Junker, Homburg (DE)
G. Salomon, Hamburg (DE)

16:40 - 16:50
Liquid biopsy: Current status and clinical perspectives
K. Pantel, Hamburg (DE)

16:50 - 17:00
cfDNA for metastasis detection and therapy monitoring in bladder cancer
L. Dyrskjøt, Aarhus (DK)

17:00 - 17:05
Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:05 - 17:15</td>
<td>Monitor the disease: Which imaging modality to follow-up drug response F. Sanguedolce, Barcelona (ES)</td>
</tr>
<tr>
<td>17:15 - 17:25</td>
<td>PSMA PET Tracers: Different tracers for different urological cancers To be confirmed</td>
</tr>
<tr>
<td>17:25 - 17:29</td>
<td>Discussion</td>
</tr>
<tr>
<td>17:29 - 17:30</td>
<td>Closing remarks R. Montironi, Ancona (IT)</td>
</tr>
</tbody>
</table>